Raxibacumab - Emergent BioSolutions

Drug Profile

Raxibacumab - Emergent BioSolutions

Alternative Names: ABthrax; PAmAb

Latest Information Update: 20 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Human Genome Sciences
  • Class Antibacterials; Antitoxins; Monoclonal antibodies
  • Mechanism of Action Anthrax toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anthrax
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anthrax

Most Recent Events

  • 03 Oct 2017 Emergent BioSolutions acquires raxibacumab from GlaxoSmithKline
  • 19 Jul 2017 Emergent BioSolutions enters into an agreement with GlaxoSmithKline to acquire raxibacumab
  • 19 Jan 2015 GlaxoSmithKline plans a phase IV immunogenicity study in Healthy volunteers in USA (NCT02339155)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top